ARTICLE | Clinical News
Ravicti glycerol phenylbutyrate regulatory update
December 7, 2015 8:00 AM UTC
The European Commission approved Ravicti glycerol phenylbutrate from Horizon to treat urea cycle disorders (UCDs) in patients ages >=2 months. In February 2013, FDA approved the pre-prodrug of phenyla...